The Medical Advisor

Muscle Mass Is a Key to Longevity  Dr Gabrielle Lyon and Dr Joseph Mercola both strongly believe muscle-centric medicine is part of the solution for many chronic health problems, including obesity, yet very little attention is given to it. "Obesity, Alzheimer's diabetes and cardiovascular disease actually begin in skeletal muscle, years before they become apparent," she says. "Obesity, diabetes, these are diseases of skeletal muscle insulin resistance. But what's so shocking is that everyone is focused, especially in the medical community, on attacking obesity, as opposed to fixing the underlying problem, which is really augmenting skeletal muscle and optimizing muscle with nutrition, which is primary, and training, secondary." As explained by Lyon, while there's certainly benefit to cardiovascular exercise — mitochondrial biogenesis, for example — resistance ...

The GLP-1 Era: Inside the “Ozempic Economy” The phrase “Ozempic economy” captures a profound shift underway in healthcare, consumer behavior, and capital markets—driven by the explosive adoption of GLP-1 receptor agonists such as Ozempic , Wegovy , Mounjaro , and Zepbound . Originally developed for type 2 diabetes, these agents are now reshaping obesity treatment—and, by extension, food systems, retail, medtech, aesthetics, and public markets. What we’re witnessing is not just a drug cycle. It’s a metabolic reset with second-order economic consequences. In less than a decade, GLP-1 receptor agonists such as  Ozempic ,  Wegovy ,  Mounjaro , and  Zepbound  have transformed obesity from a stigmatized lifestyle issue into a pharmaceutical growth engine rivaling statins in economic magnitude. This 2026 authority report examines: The science behind GLP-1 drugs Clinical outcome data and durability Capital market consequences Impact on food, fitness, aesthetics, and in...

Ivermectin and Fenbendazole in Cancer Care: A Functional Medicine Breakthrough As cancer diagnoses rise globally, the urgency for innovative, effective, and supportive therapies grows stronger. A peer-reviewed study has highlighted a groundbreaking protocol combining ivermectin, fenbendazole, and natural compounds such as Vitamin E, curcumin, and CBD. These elements, when used together, demonstrate significant potential in supporting cancer care.  The Study: A Synergistic Approach to Cancer Care The research reveals the combined effects of ivermectin, fenbendazole, and complementary compounds in addressing cancer at multiple levels. While traditionally known as antiparasitic drugs, ivermectin and fenbendazole, when used together, showed potential to modulate cancer pathways and support the body’s natural healing mechanisms. Key Findings from the Study 1. Immune System Modulation:  The protocol enhanced the immune system’s ability t...

Brain cancer, particularly aggressive forms like glioblastoma multiforme (GBM), remains one of the most formidable challenges in oncology, with limited treatment options, high recurrence rates, and dismal survival prognoses despite advances in surgery, chemotherapy, and radiation.  In recent years, however, a paradigm shift has emerged through the repurposing of established antiparasitic medications—ivermectin and mebendazole—as potential adjunctive therapies. These drugs, long proven safe for human use against parasitic infections, are now drawing attention for their anticancer properties, including the ability to target cancer stem cells, disrupt tumor metabolism, and cross the blood-brain barrier to combat intracranial malignancies.  Drawing from a surge of compelling success stories documented from 2019 (METRICS study) to 2025, this article explores more than 100 real-world case reports of patients achieving remarkable outcomes, such as tumor stabilization, shrinkage, and ...